NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Institute of Medicine (US). Addressing the Threat of Drug-Resistant Tuberculosis: A Realistic Assessment of the Challenge: Workshop Summary. Washington (DC): National Academies Press (US); 2009.

Cover of Addressing the Threat of Drug-Resistant Tuberculosis

Addressing the Threat of Drug-Resistant Tuberculosis: A Realistic Assessment of the Challenge: Workshop Summary.

Show details

References

  1. Andrews JR, Gandhi NR, Moodley P, Shah NS, Bohlken L, Moll AP, Pillay M, Friedland G, Sturm AW. Tugela Ferry Care and Research Collaboration. Exogenous reinfection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural South Africa. Journal of Infectious Diseases. 2008;198:1582–1589. [PubMed: 18847372]
  2. Ben Amor Y, Nemser B, Singh A, Sankin A, Schluger N. Underreported threat of multidrug-resistant tuberculosis in Africa. Emerging Infectious Diseases. 2008;14(9):1345–1352. [PMC free article: PMC2603092] [PubMed: 18759999]
  3. Bloom BR, Murray CJ. Tuberculosis: Commentary on a reemergent killer. Science. 1992;257(5073):1055–1064. [PubMed: 1509256]
  4. CDC (U.S. Centers for Disease Control and Prevention). Emergence of Mycobacterium tuberculosis with extensive resistance to second line drugs—worldwide, 2000–2004. Morbidity and Mortality Weekly Report. 2006;55(11):301–305. [PubMed: 16557213]
  5. CDC. Plan to combat extensively drug-resistant tuberculosis recommendations of the Federal Tuberculosis Task Force. Morbidity and Mortality Weekly Report. 2009;58(RR03):1–43. [PubMed: 19214162]
  6. CGD (Center for Global Development). A risky business: Saving money and improving global health through better demand forecasts. The report of the Center for Global Development Global Health Forecasting Working Group. 2007. [accessed January 27, 2009]. http://www​.cgdev.org​/content/publications/detail/13784.
  7. Chan ED, Iseman MD. Multidrug-resistant and extensively drug-resistant tuberculosis: A review. Current Opinion in Infectious Diseases. 2008;21(6):587–595. [PubMed: 18978526]
  8. Chou L, Harrington M, Huff B, Jefferys R, Swan T, Syed J, Wingfield C. TAG’s 2008 pipeline report. New York: Treatment Action Group; 2008.
  9. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. The growing burden of tuberculosis: Global trends and interactions with the HIV epidemic. Archives of Internal Medicine. 2003;163:1009–1021. [PubMed: 12742798]
  10. Escombe AR, Moore DA, Gilman RH, Pan W, Navincopa M, Ticona E, Martínez C, Caviedes L, Sheen P, Gonzalez A, Noakes CJ, Friedland JS, Evans CA. The infectiousness of tuberculosis patients coinfected with HIV. PLoS Medicine. 2008;5(9):e188. [PMC free article: PMC2535657] [PubMed: 18798687]
  11. Fauci AS. Multidrug-resistant and extensively drug-resistant tuberculosis: The National Institute of Allergy and Infectious Diseases research agenda and recommendations for priority research. Journal of Infectious Diseases. 2008;197(11):1493–1498. [PubMed: 18426366]
  12. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City—turning the tide. New England Journal of Medicine. 1995;333(4):229–233. [PubMed: 7791840]
  13. Friedland G. HIV/MDR-XDR-TB: Implications Speaker presentation at the Institute of Medicine Workshop on Addressing the Threat of Drug-Resistant Tuberculosis; November 5; Washington, DC. 2008.
  14. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368:1575–1580. [PubMed: 17084757]
  15. Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, Scott M, Baberia P, Marra C, Lalloo U, Friedland G. High early mortality among HIV-infected patients with multidrug-resistant (MDR) or extensively drug-resistant tuberculosis (XDR TB) in Rural South Africa. Poster presentation at 16th Conference on Retroviruses and Opportunistic Infections; Montreal. 2009.
  16. Gao Q. Transmission of MDR/XDR tuberculosis in Shanghai Speaker presentation at the Institute of Medicine Workshop on Addressing the Threat of Drug-Resistant Tuberculosis; November 5; Washington, DC. 2008.
  17. Gelmanova IY, Keshavjee S, Golubchikova VT, Berezina VI, Strelis AK, Yanova GV, Atwood S, Murray M. Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: Non-adherence, default and the acquisition of multidrug resistance. Bulletin of the World Health Organization. 2007;85(9):649–732. [PMC free article: PMC2636414] [PubMed: 18026627]
  18. Ginsberg A. TB drug development: Pipeline realities Speaker presentation at the Institute of Medicine Workshop on Addressing the Threat of Drug-Resistant Tuberculosis; November 5; Washington, DC. 2008.
  19. Global Health Forecasting Working Group. A risky business: Saving money and improving global health through better demand forecasts. Washington, DC: CGD; 2007.
  20. Goldfeld A. Drug and health care delivery: A perspective from Cambodia and Ethiopia Speaker presentation at the Institute of Medicine Workshop on Addressing the Threat of Drug-Resistant Tuberculosis; November 5; Washington, DC. 2008.
  21. IOM (Institute of Medicine). Ending neglect: The elimination of tuberculosis in the United States. Washington, DC: National Academy Press; 2000. [PubMed: 25077271]
  22. Kent PT, Kubica GP. Public health mycobacteriology: Guide for the level III laboratory. Atlanta, GA: CDC; 1985. pp. 57–63.
  23. Keshavjee S. Stemming the tide of multidrug-resistant tuberculosis: Major barriers to addressing the growing epidemic Speaker presentation at the Institute of Medicine Workshop on Addressing the Threat of Drug-Resistant Tuberculosis; November 5; Washington, DC. 2008.
  24. Keshavjee S, Seung K. Stemming the tide of multidrug-resistant tuberculosis: Major barriers to addressing the growing epidemic. 2008. [accessed February 17, 2009]. http://www​.iom.edu/Object​.File/Master/60​/204/IOM_MDRTB_whitepaper​_2009_01_14_FINAL_Edited.pdf.
  25. Lucas SB, Hounnou A, Peacock C, Beaumel A, Djomand G, N’Gbichi JM, Yeboue K, Honde M, Diomande M, Giordano C, et al. The mortality and pathology of HIV infection in a West African City. AIDS. 1993;7(12):1569–1579. [PubMed: 7904450]
  26. Ministry of Health of the People’s Republic of China. Nationwide random survey for the epidemiology of tuberculosis in 2000: Ministry of Public Health of the People’s Republic of China, 2000. Beijing, China: Ministry of Health of the People’s Republic of China; 2000.
  27. Moe J. Continuing challenge of clinical trial failure: New incentives for neglected disease innovation Speaker presentation at the Institute of Medicine Workshop on Addressing the Threat of Drug-Resistant Tuberculosis; November 5; Washington, DC. 2008.
  28. Mohar A, Romo J, Salido F, Jessurun J, Ponce de Leon S, Reyes E, Volkow P, Larraza O, Peredo MA, Cano C, Gomez G, Sepúlveda J, Mueller N. The spectrum of clinical and pathological manifestations of AIDS in a consecutive series of autopsied patients in Mexico. AIDS. 1992;6(5):467–473. [PubMed: 1616652]
  29. Moll T, Gandhi NR, Sturm AW, Andrews J, Shah NS, Lalloo UG, Moodley P, Friedland G. Extensively drug-resistant (XDR) TB now more common than MDR-TB in Tugela Ferry, KwaZulu-Natal, South Africa. Poster discussion presented at the 38th Union World Conference on Lung Health; Cape Town. 2007.
  30. Moodley P, Moll T, Shah NS, Gandhi NR, Friedland G, Lalloo UG, Andrews J, Sturm AW. Multidrug- and extensively drug-resistant tuberculosis in KwaZulu-Natal. Poster discussion presented at the 38th Union World Conference on Lung Health; Cape Town. 2007.
  31. Nardell E. How did we get to where we are today? Lack of institutional tuberculosis transmission control Speaker presentation at the Institute of Medicine Workshop on Addressing the Threat of Drug-Resistant Tuberculosis; November 5; Washington, DC. 2008.
  32. Nelson AM, Perriens JH, Kapita B, Okonda L, Lusamuno N, Kalengayi MR, Angritt P, Quinn TC, Mullick FG. A clinical and pathological comparison of the WHO and CDC case definitions for AIDS in Kinshasa, Zaire: Is passive surveillance valid? AIDS. 1993;7(9):1241–1245. [PubMed: 8216982]
  33. Nunn P. Global incidence of MDR and XDR-TB Speaker presentation at the Institute of Medicine Workshop on Addressing the Threat of Drug-Resistant Tuberculosis; November 5; Washington, DC. 2008.
  34. Pillay M, Sturm AW. Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clinical Infectious Diseases. 2007;45:409–414. [PubMed: 17990220]
  35. Porter ME. Why America needs an economic strategy: The Harvard Business School competitiveness guru offers his prescription for long-term prosperity. 2008. [accessed January 28, 2009]. http://www​.businessweek​.com/magazine/content​/08_45/b4107038217112.htm.
  36. Ridderhof J. Laboratory capacity: A global analysis Speaker presentation at the Institute of Medicine Workshop on Addressing the Threat of Drug-Resistant Tuberculosis; November 5; Washington, DC. 2008.
  37. Ridley DB, Grabowski HG, Moe JL. Developing drugs for developing countries. Health Affairs (Millwood) 2006;25(2):313–324. [PubMed: 16522573]
  38. Shah NS, Wright A, Bai GH, Barrera L, Boulahbal F, Martín-Casabona N, Drobniewski F, Gilpin C, Havelková M, Lepe R, Lumb R, Metchock B, Portaels F, Rodrigues MF, Rüsch-Gerdes S, Van Deun A, Vincent V, Laserson K, Wells C, Cegielski JP. Worldwide emergence of extensively drug-resistant tuberculosis. Emerging Infectious Diseases. 2007;13(3):380–387. [PMC free article: PMC2725916] [PubMed: 17552090]
  39. Shah NS, Pratt R, Armstrong L, Robison V, Castro KG, Cegielski JP. Extensively drug-resistant tuberculosis in the United States, 1993–2007. Journal of the American Medical Association. 2008;300(18):2153–2160. [PubMed: 19001626]
  40. Sloutsky A. Untitled presentation Speaker presentation at the Institute of Medicine Workshop on Addressing the Threat of Drug-Resistant Tuberculosis; November 5; Washington, DC. 2008.
  41. TB Alliance and the Global Alliance for TB Drug Development. Pathway to patients: Charting the dynamics of the global TB drug market. 2007. [accessed January 27, 2009]. http://www​.bvgh.org/documents​/TB_Alliance​_Pathway_to_Patients_FINAL.pdf.
  42. Towse A, Kettler H. Advance price or purchase commitments to create markets for treatments for diseases of poverty: Lessons from three policies. Bulletin of the World Health Organization. 2005;83(4):301–307. [PMC free article: PMC2626206] [PubMed: 15868022]
  43. Weyer K, Ridderhof J.GLI Working Group. Symposium presentation at the World Congress on Lung Health in Capetown; South Africa. November 7–8.2007.
  44. Willingham FF, Schmitz TL, Contreras M, Kalangi SE, Vivar AM, Caviedes L, Schiantarelli E, Neumann PM, Bern C, Gilman RH. the Working Group on TB in Peru. Hospital control and multidrug-resistant pulmonary tuberculosis in female patients, Lima, Peru. Emerging Infectious Diseases. 2001;7(1):123–127. [PMC free article: PMC2631673] [PubMed: 11266302]
  45. WHO (World Health Organization). The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance 1994–1997. Geneva, Switzerland; WHO: 1997. Anti-tuberculosis drug resistance in the world.
  46. WHO. The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance. Geneva, Switzerland: WHO; 2000. Anti-tuberculosis drug resistance in the world, report no.2, prevalence and trends.
  47. WHO. The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance. Geneva, Switzerland: WHO; 2004. Anti-tuberculosis drug resistance in the world, third global report.
  48. WHO. Global tuberculosis control 2008: Surveillance, planning, financing. Geneva, Switzerland: WHO; 2008a.
  49. WHO. Anti-tuberculosis drug resistance in the world, fourth global report by the WHO/IUATLD Global project on anti-tuberculosis drug resistance surveillance. Geneva, Switzerland: WHO; 2008b.
  50. WHO. TB/HIV facts. 2008c. [accessed February 17, 2009]. http://www​.who.int/tb​/challenges/hiv/tbhiv_facts08_en.pdf.
  51. Willingham FF, Schmitz TL, Contreras M, Kalangi SE, Vivar AM, Caviedes L, Schiantarelli E, Neumann PM, Bern C, Gilman RH. the Working Group on TB in Peru. Hospital control and multidrug-resistant pulmonary tuberculosis in female patients, Lima, Peru. Emerging Infectious Diseases. 2001;7(1):123–127. [PMC free article: PMC2631673] [PubMed: 11266302]
  52. Zhao M, Li X, Xu P, Shen X, Gui X, Wang L, DeRiemer K, Mei J, Gao Q. Transmission of MDR and XDR tuberculosis in Shanghai, China. PLoS One. 2009;4(2):e4370. [PMC free article: PMC2631152] [PubMed: 19190774] [Cross Ref]
  53. Zignol M, Hosseini MS, Wright A, Lambregts-van Weezenbeek C, Nunn P, Watt CJ, Williams BG, Dye C. Global incidence of multidrug-resistant tuberculosis. Journal of Infectious Diseases. 2006;194(4):479–485. [PubMed: 16845631]
  54. Zintl P. Supply and demand for quality-assured second line TB drugs Speaker presentation at the Institute of Medicine Workshop on Addressing the Threat of Drug-Resistant Tuberculosis; November 5; Washington, DC. 2008.
Copyright © 2009, National Academy of Sciences.
Bookshelf ID: NBK44998

Views

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...